tbuckley/cabot-search huggingface dataset:
Medulloblastoma: Clinical and biologic aspects
Authors: R. J. Packer
Journal: Neuro-Oncology (1999)

Neuro-OncologyMedulloblastoma is the most common childhood primary CNS tumor, and treatment approaches have evolved over the past three decades.The biologic underpinnings of medulloblastoma are not fully characterized, but recent work has identi ed new, important directions for research.Strati cation of patients with medulloblastoma into risk groups is the backbone of most ongoing therapeutic studies.Patients are usually characterized as being either average risk or poor risk, although an intermediate risk group may exist.Standard treatment for older children with medulloblastoma consists of radiation and, for most, chemotherapy.Children with nondisseminated disease at the time of diagnosis have been reported to have as high as an 80% ve-year disease-free survival rate after treatment with reduced dose (2340 cGy) craniospinal irradiation, local boost radiation therapy (5500 cGy), and chemotherapy, given during and after radiation therapy.Preradiation chemotherapy has yet to be shown to be of bene t for children with medulloblastoma.Children with disseminated disease are a highly problematic subgroup of patients to treat.A variety of new approaches are being studied, most of which are intensifying chemotherapy either prior to or after radiation.Long-term survivors of medulloblastoma are at signi cant risk for permanent endocrinologic, cognitive, and psychological sequelae.Infants and very young children with medulloblastoma remain a dif cult therapeutic challenge because they have the most virulent form of the disease and are at highest risk for treatment-related sequelae.
Bipolar Affective Puerperal Psychosis: Genome-Wide Significant Evidence for Linkage to Chromosome 16
Authors: Ian Jones, Marian Hamshere, Jeanne-Marrie Nangle, Philip Bennett, Elaine Green, Jess Heron, Ricardo Segurado, David Lambert, Peter Holmans, Aiden Corvin, Mike Owen, Lisa Jones, Michael Gill, Nick Craddock
Journal: American Journal of Psychiatry (2007)

Objective: Vulnerability to the triggering of bipolar episodes by childbirth aggregates in families and may define a genetically relevant subtype of bipolar disorder. The authors conducted a search by systematic whole genome linkage scan for loci influencing vulnerability to bipolar affective puerperal psychosis. Method: The authors selected families with bipolar disorder from their previous bipolar disorder genome scan, in which there was at least one family member with a manic or psychotic episode with an onset within 6 weeks of delivery. Individuals were coded as affected if they had been diagnosed with bipolar I disorder; bipolar II disorder; or schizoaffective disorder, bipolar type, according to DSM-IV. A total of 36 pedigrees contributed 54 affected sibling pairs to the cohort. A genome scan with 494 microsatellite markers was analyzed using GENEHUNTER and MAPMAKER/SIBS. Results: A genome-wide significant linkage signal was observed on chromosome 16p13, and a genome-wide suggestive linkage was observed on chromosome 8q24. No significant or suggestive linkage was observed in these regions in our original bipolar scan. Conclusions: This study identifies chromosomal regions that are likely to harbor genes that predispose individuals to bipolar affective puerperal psychosis. The identification of susceptibility genes would enhance understanding of pathogenesis and offer the possibility of improvements in treatment and risk prediction.
A ?fantasy island? for tropical biogeochemistryNutrient Cycling and Limitation by Peter Vitousek. Princeton University Press, 2004. US$dollar;79.50, E52.95/US$dollar;35.00, E22.95 hbk/pbk (232 pages) ISBN 0 691 11579 6/0 691 11580 X
Authors: L MARTINELLI
Journal: Trends in Ecology & Evolution (2004)
MOLDY PEANUTS AND LIVER CANCERS
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CLIMATIC INFLUENCE IN PHTHISIS
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium.
Authors: E. J. Small, T. M. Beer, V. K. Weinberg, C. S. Higano, L. T. Nordquist, J. E. Rosenberg, J. J. Alumkal, E. Y. Yu, J. Sun, A. M. Lin
Journal: Journal of Clinical Oncology (2010)

4684 Background: Docetaxel remains the standard of care for patients (pts) with mCRPC. However the optimal duration of chemotherapy (Ch) is not known. Providing Ch holidays is often undertaken, but not well characterized. A randomized phase II trial was undertaken to test two ICh regimens. Methods: Pts with Ch naive mCRPC and KPS > 60% were eligible. Pts were treated with “induction” docetaxel 75 mg/m2 q 3 weeks, and prednisone 5 mg po bid. After 6 cycles, responding pts (PSAWG1 criteria) stopped Ch and were randomized to observation (Obs) or to GM-CSF, 250 mcg/m2 sq daily for 14 days out of every 28 day cycle. Pts were followed with monthly PSA and imaging every 2 cycles until progressive disease (PD) by PSAWG1 criteria, at which point they resumed treatment with Ch, again for 6 cycles, followed by the same “off Ch” regimen. The primary endpoint was the time to PD while on Ch (time to Ch resistance). Results: Of 66 enrolled pts to date, 58 are evaluable (8 are still undergoing induction). 41 pts completed induction (17 did not due to PD, adverse events (AE), or MD choice), of which 14 had PD after 6 cycles. Thus, 27/58 evaluable pts (47%) were eligible for randomization. Of these, 14 pts underwent Obs and 13 received GM-CSF. To date, 16/27 (59%) pts who underwent a Ch holiday restarted Ch, all for PSA PD. 4/16 had a response to Ch re-initiation. (8 pts did not re-start Ch because of AE or other therapy being started, and 3 pts are still undergoing either Obs or GM-CSF.) Obs pts were “off Ch” for 29% of the total cycle time, compared with 42.5% for GM-CSF pts. Conclusions: While feasible, only 47% of pts met criteria for ICh. 25% of pts responded to Ch re-initiation. Insufficient data exist to assess the impact of GM-CSF on time off Ch or time to Ch resistance. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration sanofi-aventis
P2.01-116 The Potential of Assessing Blood Tumor Mutation Burden (bTMB) Using a Large Panel
Authors: K. Zhang, Y. Tang, X. Xu, W. Tao, Z. Rao, F. Wu, S. An, J. Liu, J. Yang, T. Hou, L. Zhang, Y. Zhang, L. Liu, S. Zhang
Journal: Journal of Thoracic Oncology (2018)
ACTR-19. REPORT ON THE COMBINATION OF AXITINIB AND TUMOR TREATING FIELDS (TTFIELDS) IN THREE PATIENTS WITH RECURRENT GLIOBLASTOMA
Authors: Ellina Schulz, Almuth F Kessler, Judith Weiland, Thomas Linsenmann, Ralf-Ingo Ernestus, Carsten Hagemann, Mario Löhr
Journal: Neuro-Oncology (2019)

Abstract OBJECTIVE Tumor Treating Fields (TTFields) significantly improved survival of newly diagnosed glioblastoma (ndGBM) patients in the EF-14 trial. Axitinib is an orally available tyrosine kinase inhibitor which is approved for the treatment of metastatic renal cell carcinoma. It has a high affinity and specificity for vascular endothelial growth factor receptors. In phase 2 trials, Axitinib improved response rate and PFS in recurrent GBM (rGBM) patients with a manageable toxicity profile. Here, three rGBM patients treated with TTFields and Axitinib (AxiTTFields) are presented. PATIENT SECTION A 53-year-old male patient (#1) presented with a progressing GBM after initial surgery, radiochemotherapy followed by 4 cycles of temozolomide (TMZ) and TTFields. In a 46-year-old male patient (#2), early progress occurred after surgery, radiochemotherapy and 3 cycles of TMZ combined with TTFields. In both patients Axitinib was added to the treatment regimen to meet the urgent need of an alternative treatment. In a 61-year-old male patient (#3) with rGBM after surgery, radiochemotherapy and 6 cycles of TMZ, TTFields therapy was initiated at recurrence and the treatment regimen was adapted to AxiTTFields. RESULTS No additional adverse events due to the combined therapy of AxiTTFields were observed. Patients #1 and #2 were on AxiTTFields therapy for more than 8 months, presenting an improved neurological status with a partial response in the MRI 3 months after initiating AxiTTFields. #3 declined in his neurological status without any change in the MRI monitoring and died 2.4 months after initiating AxiTTFields. With an average of 77%, the TTFields usage rate was above the independent prognostic threshold of 75%, underlining the feasibility of this approach. CONCLUSION AxiTTFields was feasible and safe in three rGBM patients. The addition of Axitinib to TTFields therapy is a promising approach and safety/feasibility will be further investigated in a pilot trial.
Cutaneous Cryptococcus infection due to C. albidus associated with Sezary syndrome
Authors: S. Narayan, K. Batta, P. Colloby, C.Y. Tan
Journal: British Journal of Dermatology (2000)

Journal Article Cutaneous Cryptococcus infection due to C. albidus associated with Sézary syndrome Get access S. Narayan, S. Narayan Department of Dermatology, The Birmingham Skin Centre and Search for other works by this author on: Oxford Academic Google Scholar K. Batta, K. Batta Department of Dermatology, The Birmingham Skin Centre and Search for other works by this author on: Oxford Academic Google Scholar P. Colloby, P. Colloby Department of Histopathology, City Hospital, Birmingham B18 7QH, U.K. Search for other works by this author on: Oxford Academic Google Scholar C.Y. Tan C.Y. Tan Department of Dermatology, The Birmingham Skin Centre and Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 143, Issue 3, 1 September 2000, Pages 632–634, https://doi.org/10.1111/j.1365-2133.2000.03724.x Published: 01 September 2000
Neurofibromatosis
Authors: Janet M. Torpy
Journal: JAMA (2008)

NeurofibromatosisN eurofibromatosis (NF) is a genetic disorder causing skin abnormalities and tumors that form on nerve tissues.These tumors can be small or large and can occur anywhere in the body, including the brain, spinal cord, large nerves, or smaller nerves.NF affects persons of both sexes and all racial groups.There are 2 types of neurofibromatosis, called NF1 and NF2.These are 2 distinct disorders that are caused by mutations (changes) in different genes.NF1 is also referred to as Von Recklinghausen disease and is a rather common genetic disease, affecting approximately 1 in 4000 individuals.Some patients who have NF1 only display characteristic skin abnormalities such as café-au-lait spots, which are flat, hyperpigmented (darker than surrounding skin) areas.Other patients can have severe physical complications such as malignant (cancerous) tumors or have mental retardation.The July 16, 2008, issue of JAMA includes an article about the learning deficits associated with NF.Learning disability is the most frequent complication in children with NF1.NF2 is much more rare than NF1, affecting less than 1 in 30 000 individuals, usually becoming apparent in the late teens, and typically causing hearing loss and problems with balance due to tumors on nerves to the ears.
The Yamagiwa-Yoshida Memorial International Cancer Study Grants
Journal: JNCI Journal of the National Cancer Institute (1978)

Journal Article The Yamagiwa-Yoshida Memorial International Cancer Study Grants Get access JNCI: Journal of the National Cancer Institute, Volume 61, Issue 3, September 1978, Page 939, https://doi.org/10.1093/jnci/61.3.939 Published: 01 September 1978
Potassium and apoptosis.
Journal: Environmental Health Perspectives (1997)

Potassium and ApoptosisScientists in the Laboratory of Signal Transduction at the NIEHS have broken new ground in the study of the effect of ions, particularly potassium (K+), on apoptosis, or "programmed cell death."It is known that apoptosis plays an important role in the development of disease, but little is under- stood about how this mechanism works.In two papers soon to be published in the Journal ofBiological Chemistry, investigators John Cidlowski, Carl Bortner, and Francis Hughes, Jr. explain that the loss of K+ from a cell is a necessary precursor to apoptosis.This is a reversal in the understanding of the role of ion flux in apoptosis; it was thought
Omitted Sentences in Conclusions and Relevance
Journal: JAMA Cardiology (2017)

Marshall B. Elam, PhD, MD; Henry N. Ginsberg, MD; Laura C. Lovato, MS; Marshall Corson, MD; Joseph Largay, PA-C; Lawrence A. Leiter, MD; Carlos Lopez, MD, MS; Patrick J. O’Connor, MD, MPH; Mary Ellen Sweeney, MD; Daniel Weiss, MD; William T. Friedewald, MD; John B. Buse, MD, PhD; Hertzel C. Gerstein, MD; Jeffrey Probstfield, MD; Richard Grimm, MD, PhD; Faramarz Ismail-Beigi, MD, PhD; David C. Goff Jr, MD, PhD; Jerome L. Fleg, MD; Yves Rosenberg, MD; Robert P. Byington, PhD; for the ACCORDION Study Investigators
This Week in &lt;emph&gt;JAMA&lt;/emph&gt;
Journal: JAMA (2009)

A Piece of My Mind" [Dawn] looked up and began to speak in short gasps.She wanted to go home.She wanted the central venous catheter removed.She was not interested in further transfusions or antibiotics."From "Giving Up." SEE PAGE 1747 Medical News & PerspectivesA new guideline recommends offering finasteride to asymptomatic men being screened for prostate cancer to reduce their risk for developing the disease, even though the drug does not lower mortality rates.
Selected Abstracts
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Central review of discordant samples for microarray-based ER, PR, and HER2 and local IHC/FISH assessment worldwide from 827 patients.
Authors: Jelle Wesseling, Corrado Tinterri, Anna Sapino, Fabrizio Zanconati, Martijn Lutke Holzik, Bichlien Nguyen, Kenneth B. Deck, Patrizia Querzoli, Tiziana Perin, C Giardina, Gerhard Seitz, Jean-Marc Guinebretiere, Julie Barone, Toru Watanabe, Femke De Snoo, Lisette Stork-Sloots, Pino Cusumano
Journal: Journal of Clinical Oncology (2012)

11 Background: Differences in fixation and IHC and subjective interpretation can substantially affect the accuracy and reproducibility of estrogen receptor (ER), progesterone receptor (PR) and HER2 expression. The commercially available TargetPrint test measures the mRNA expression level of ER, PR and HER2 and is 98% concordant with centrally assessed ER as presented by Viale et al, SABCS 2011. This study compares results from the microarray-based TargetPrint with IHC and FISH (for HER2 IHC2+) generated by local standard procedures. Methods: Fresh tumor samples (core needle biopsies or surgical) were collected for 831 patients diagnosed with breast cancer stage I to IV (Feb 2008 - Jan 2011) from 22 hospitals from Europe, New Zealand, Japan and US. The results of the IHC/FISH assessments performed according to the local standards at the hospitals were compared to the quantitative gene expression readouts with TargetPrint. Discordant cases were centrally reviewed for IHC/FISH assessment. Results: Of the 831 samples, IHC assessment was unknown for 4 ER/ PR samples; HER2 was unknown for 12 samples. Comparison of IHC and gene expression read out by TargetPrint showed a concordance of 95% for ER; 83% for PR and 94% for HER2. In this study, 3% of all IHC ER positive samples were classified negative by microarray, and 11% of IHC PR positive samples were classified negative by microarray. For HER2, 4% of IHC/FISH HER2 positive samples were classified negative by microarray and 2% of IHC/FISH HER2 negative samples were classified positive by microarray. Most notably, all available 5 ER IHC negative/TargetPrint positive samples turned out to be positive with central re-assessment. HER2 IHC2+ samples with discordant classifications for TargetPrint and local assessment are currently being reviewed for FISH/SISH assessment. Conclusions: Microarray based readout of ER, PR and HER2 status using TargetPrint is fairly comparable to local IHC and FISH analysis in 827 analyzed samples in various hospitals worldwide. However, re-assessment of discordant cases–especially IHC ER-/TargetPrint ER+ cases- confirms TargetPrint to be a useful high quality second opinion for local IHC/FISH assessment.
Abstract 17601: Left Atrial function Assessed by Cardiac Magnetic Resonance Imaging in Patients With Heart Failure With Preserved and Reduced Left Ventricle Ejection Fraction With and Without Symptoms
Authors: Naila Choudhary, Michael Passick, Javed Butler, Nathaniel Reichek, Jie J Cao
Journal: Circulation (2015)

Introduction: Increased left atrial volume (LAV) is considered a barometer for impaired left ventricular (LV) relaxation. In this study we examined the LAV and LA emptying function in patients with LV systolic (LVSD) and diastolic dysfunction (LVDD) with and without clinical heart failure (HF). Methods: Prospectively enrolled study participants (n=66) underwent cardiac MR (CMR) in a 1.5 T scanner. Patients with atrial fibrillation were excluded. LAV was assessed at end systole (ES) and at end diastole (ED) using area-length methods in cine MR 4-chamber and 2-chamber planes and indexed to body surface area. HF status was based on clinical manifestations, elevated BNP or NT-BNP. Patients also underwent echocardiogram within 2 hours of CMR. LV ejection fraction (LVEF) by CMR &lt; 50% was defined as LVSD. Echocardiographic criteria and/or elevated LVED pressure by catheterization were applied to define LVDD. Results: LAV was significantly increased in HF patients. The greatest increase was seen among those with HFrEF. When compared to normal controls the magnitude of increase in LAV in HF patients was greater at ED than ES. Patients having LVSD and LVDD without clinical HF demonstrated relatively normal LAV at both ES and ED. While LA emptying function was significantly reduced in all HF patients the greatest reduction was found in HFpEF. LA boost function in late diastole was significantly increased only in LVDD (Table). Of the three LA indices, LA emptying function had the strongest correlation with (logarithm transformed) BNP (r = -0.62, p &lt;0.001) and NT-BNP (r = -0.58, p &lt;0.001) supporting its relationship with adverse hemodynamics. Conclusion: Significantly increased LAV and reduced LA emptying function were present in HFrEF and HFpEF. Heightened LA boost function with relatively normal LAV and emptying function was characteristic of LVDD without HF. These LA features demonstrate the importance of atrioventricular interdependence and may be valuable in clinical diagnosis.
Précis de chimie physiologique.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal